Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ

Wei Wei, Paul A. Dutchak, Xunde Wang, Xunshan Ding, Xueqian Wang, Angie L. Bookout, Regina Goetz, Moosa Mohammadi, Robert D. Gerard, Paul C. Dechow, David J. Mangelsdorf, Steven A. Kliewer, Yihong Wan

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gain of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bonemarrowmesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.

Original languageEnglish (US)
Pages (from-to)3143-3148
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number8
DOIs
StatePublished - Feb 21 2012

Fingerprint

Peroxisome Proliferator-Activated Receptors
Bone and Bones
rosiglitazone
Adipogenesis
fibroblast growth factor 21
Bone Remodeling
Lipid Metabolism
Type 2 Diabetes Mellitus
Energy Metabolism
Homeostasis
Stem Cells
Hormones
Glucose

Keywords

  • Adipocyte
  • Bone metabolism
  • Nuclear receptor
  • Osteoblast
  • Thiazolidinediones

ASJC Scopus subject areas

  • General

Cite this

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. / Wei, Wei; Dutchak, Paul A.; Wang, Xunde; Ding, Xunshan; Wang, Xueqian; Bookout, Angie L.; Goetz, Regina; Mohammadi, Moosa; Gerard, Robert D.; Dechow, Paul C.; Mangelsdorf, David J.; Kliewer, Steven A.; Wan, Yihong.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 8, 21.02.2012, p. 3143-3148.

Research output: Contribution to journalArticle

Wei, Wei ; Dutchak, Paul A. ; Wang, Xunde ; Ding, Xunshan ; Wang, Xueqian ; Bookout, Angie L. ; Goetz, Regina ; Mohammadi, Moosa ; Gerard, Robert D. ; Dechow, Paul C. ; Mangelsdorf, David J. ; Kliewer, Steven A. ; Wan, Yihong. / Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 8. pp. 3143-3148.
@article{341449b514074afa8c5a1ca0e969b8dc,
title = "Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ",
abstract = "The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gain of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bonemarrowmesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.",
keywords = "Adipocyte, Bone metabolism, Nuclear receptor, Osteoblast, Thiazolidinediones",
author = "Wei Wei and Dutchak, {Paul A.} and Xunde Wang and Xunshan Ding and Xueqian Wang and Bookout, {Angie L.} and Regina Goetz and Moosa Mohammadi and Gerard, {Robert D.} and Dechow, {Paul C.} and Mangelsdorf, {David J.} and Kliewer, {Steven A.} and Yihong Wan",
year = "2012",
month = "2",
day = "21",
doi = "10.1073/pnas.1200797109",
language = "English (US)",
volume = "109",
pages = "3143--3148",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ

AU - Wei, Wei

AU - Dutchak, Paul A.

AU - Wang, Xunde

AU - Ding, Xunshan

AU - Wang, Xueqian

AU - Bookout, Angie L.

AU - Goetz, Regina

AU - Mohammadi, Moosa

AU - Gerard, Robert D.

AU - Dechow, Paul C.

AU - Mangelsdorf, David J.

AU - Kliewer, Steven A.

AU - Wan, Yihong

PY - 2012/2/21

Y1 - 2012/2/21

N2 - The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gain of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bonemarrowmesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.

AB - The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gain of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bonemarrowmesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.

KW - Adipocyte

KW - Bone metabolism

KW - Nuclear receptor

KW - Osteoblast

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=84863116228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863116228&partnerID=8YFLogxK

U2 - 10.1073/pnas.1200797109

DO - 10.1073/pnas.1200797109

M3 - Article

VL - 109

SP - 3143

EP - 3148

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -